Intellia Therapeutics Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.32%.
Did NTLA Beat Earnings? Q4 2025 Results
Intellia Therapeutics delivered a notably strong fourth quarter, with shares climbing more than 10% after the gene-editing company posted an adjusted loss of $0.83 per share, well ahead of the consensus estimate of $0.96 and representing a 13.71% beat, while collaboration revenue of $23.02 million nearly doubled year-over-year, coming in 89.08% above the $12.17 million analysts had expected. The primary driver behind the revenue outperformance was a $9.00 million recognition tied to the termination of the SparingVision license agreement, combined with higher cost reimbursements from the Regeneron collaboration, pushing full-year revenue growth to 78.8%. Net loss also narrowed sharply to $95.79 million from $128.90 million a year ago, aided by a meaningful pullback in R&D spending. Looking ahead, Intellia expects topline data from its fully enrolled HAELO Phase 3 trial for lonvo-z in hereditary angioedema by mid-2026, with a BLA submission planned for the second half of 2026 and a U.S. commercial launch targeted for early 2027, supported by approximately $605 million in cash the company says will fund operations into the second half of 2027.
- Recognition of $9.0 million in revenue from termination of SparingVision license and collaboration agreement
- Increased cost reimbursements from Regeneron collaboration
- Reduction in R&D expenses by $28.2 million year-over-year in Q4 driven by lower employee-related costs, stock-based compensation, and contracted services
“2025 was a time of accomplishment and resiliency for Intellia as we presented encouraging longer term Phase 1/2 clinical data for both lonvo-z and nex-z, rapidly enrolled patients in our three Phase 3 trials, commenced activities to prepare for a potential lonvo-z launch in HAE and responded to the clinical holds on our nex-z Phase 3 trials late in the year.”
Intellia Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Intellia expects HAELO Phase 3 topline data for lonvo-z in HAE by mid-2026 and, if supportive, plans to submit a BLA to the FDA in the second half of 2026 with an anticipated U.S. commercial launch in the first half of 2027. The company is reactivating global sites for the MAGNITUDE-2 Phase 3 trial of nex-z in ATTRv-PN following the FDA's lifting of the clinical hold, with enrollment completion expected in the second half of 2026. The clinical hold on MAGNITUDE (nex-z for ATTR-CM) remains unresolved with ongoing FDA engagement. Cash, cash equivalents and marketable securities of approximately $605 million are expected to fund operations into the second half of 2027 and through the anticipated lonvo-z U.S. launch.
NTLA YoY Financials
NTLA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.